Blood Cancer Press releases

Ipsogen’s JAK2 MutaQuant™ assay chosen to monitor molecular response in two large international leukemia trials on Polycythemia Vera and Essential Thrombocythemia

IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN / Frankfurt, Prime Standard: QIA), today announced that its JAK2 MutaQuant™ assay has been selected by the MyeloProliferative Disorders Research Consortium (MPD-RC) to assess the JAK V617F mutation load in two in...[more]

EHA 2011: IPSOGEN to present its first multicentre study on the IS-MMR BCR-ABL assay

The study, run in 14 European and US molecular laboratories, documents the added value of the IS-MMR BCR-ABL assay to convert results on the International Scale and ensure inter-laboratory standardisation.[more]

IPSOGEN acquires a License from Stanford University on LNK mutations

IPSOGEN  (Alternext  - FR0010626028 – ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces the signature of an agreement with Stanford University for the worldwide license on genomic mutations in the ...[more]

IPSOGEN calibrates its BCR-ABL assays to the International Scale, a new progress in Chronic Myeloid Leukemia management

IPSOGEN (Alternext - FR0010626028 - ALIPS), Cancer Profiler, who develops, manufactures and commercializes molecular diagnostic assays for leukemia and breast cancer, announces today the official launch of its new line of assays that enables standardization of quantitative analysis of BCR-ABL  ...[more]

IPSOGEN Strengthens its Patent Position with U.S. Allowance of Additional JAK2 V617F Claims

IPSOGEN (Alternext - FR0010626028 - ALIPS) announced today that the United States Patent and Trademark Office (USPTO) has allowed claims that strengthen the company’s patent position for the detection and diagnostic use of the JAK2 V617F mutation.

More[more]

IPSOGEN Obtains Option to Acquire License on TET2 abnormalities to improve the Diagnosis of Blood-based Disorders

IPSOGEN today announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene. The scientific corpus supporting these TET2 patent rights has been developed by a consortium of 7 public institutions led by IGR&D, the technology trans...[more]

Scientific Publications: Standardised WT1 assay developed by the European LeukemiaNet (ELN) consortium

An international collaborative study coordinated by the European Leukemia Network (ELN) consortium on standardisation of WT1 testing for risk stratification in Acute Myeloid Leukemia has been published in the November 2009 issue of the Journal of Clinical Oncology.

The objective of this study was t...[more]

Ipsogen expands its IVD offer in leukemia diagnostic with the CE marking of JAK2 MutaQuant™ and JAK2 MutaSearch™ Kits

JAK2 MutaQuant™ and MutaSearch™ Kits are now CE marked![more]

Next Events

Ipsogen is participating to a great number of international congresses. Ipsogen’s team will be happy to meet you and discuss your current needs and find out about Ipsogen’s latest developments.

ESH-CML 2009 ESH Eleventh International Conference Chronic Myeloid Leukaemia - Biological Basis of Therap...[more]

Ipsogen further expands its offer in leukemia diagnostic, including two new JAK2 V617F detection kits and a new kit for NPM1 mutations in Acute Myeloid Leukemia

Two new JAK2 V617F detection kits

JAK2 V617F MutaSearchTM Kit: a new multiplatform kit compatible with LightCycler® 1.2 & 1.5 systems In order to better address laboratory needs, IPSOGEN developed a new JAK2 V617F detection assay based on allele specific technology, making it compatible with al...[more]